Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpFN + ALFQ
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intradermal
01
Overview
SpFN + ALFQ (Spike Ferritin Nanoparticle adjuvanted with Army Liposome Formulation containing QS-21) is a next-generation recombinant protein subunit nanoparticle vaccine candidate developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and the University of Pittsburgh. The vaccine is designed to provide broad and durable protection against SARS-CoV-2 (COVID-19) and other coronaviruses (pan-sarbecovirus). It consists of multiple SARS-CoV-2 spike proteins linked to the surface of a self-assembling ferritin nanoparticle, formulated with the potent ALFQ adjuvant (which contains monophosphoryl lipid A and QS-21). In addition to intramuscular administration, a dissolvable microneedle patch (MNP) formulation is being developed by the University of Pittsburgh to enable needle-free, thermostable delivery.
- Other names
- SpFN + ALFQ MNPSpFN-ALFQSpFN/ALFQSpFN/ALFQ MNP
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spikeTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on SpFN + ALFQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpFN + ALFQ.